Skip to main content

VIDAS® SARS-COV-2 

Two immunoassay tests to detect IgM & IgG antibodies

VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG II automated assays rapidly detect antibodies to help identify individuals with previous exposure to SARS-CoV-2.

  

Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.

VIDAS SARS-COV-2

Overview

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel coronavirus discovered in China in December 2019 that has led to an unprecedented global pandemic. It causes coronavirus disease 19 (COVID‑19), a respiratory illness with symptoms ranging from mild to severe with possible progression to pneumonia, multiorgan failure, and even to death. Identification of individuals who have been infected by this new virus is key for better management of the patients and to face the COVID-19 health crisis.

VIDAS® SARS-COV-2 IgM (9COM) and VIDAS® SARS-COV-2 IgG II (9COG) use a two-step sandwich enzyme immunoassay method with a final fluorescence detection (ELFA). For use on any VIDAS® instrument, they offer flexibility and reliability for results in less than 30 minutes.

  

VIDAS® SARS-COV-2 Advantages

  • Single dose automated tests for greater flexibility
  • All-inclusive, small-size kits
    • Security and simplicity with less handling
    • Long shelf life (12 months) and easy storage
    • Reagents ready-to-use in sealed, single-use strips
  • Two tests with same protocols to differentiate IgM & IgG results:
    • VIDAS® SARS-COV-2 IgM to detect IgM specific for SARS-CoV-2
    • VIDAS® SARS-COV-2 IgG II to detect IgG specific for SARS-CoV-2

Rapid Results You Can Count On

  • Available on-demand 24/7 on all VIDAS® platforms
  • Reliable results in less than 30 minutes
  • Performance with high specificity and sensitivity from day 8
  • Results help provide additional pandemic analysis data

Ease of Use on any VIDAS® Instrument

  • Automated ELFA technology
  • All assay steps performed automatically by instrument
  • Intuitive and easy to use
  • Limited maintenance, calibration, and controls

VIDAS® Solutions

  • Reliable and easy-to-use instruments with random access and small footprint. 
  • Well adapted to rapid response laboratories.
  • Factory-calibrated, Single-dose tests which reduce the need for additional controls.
  • Short time to result.
  • Reagents can be used immediately after removal from the refrigerator.

Assays

Technical Specifications

AssaysReferenceCodeTests per KitTime to ResultDecisional Cut-Offs
VIDAS® SARS-COV-2 IgG II424114-609COG60 tests27 minSemi Quantitative Test: Positive, Negative
VIDAS® SARS-COV-2 IgM423833-609COM60 tests27 minQualitative Test: Negative, Positive

BECAUSE IT MAKES SENSE ON VIDAS®

Resources

VIDAS® SARS-COV-2 Brochure 

Download

Related Products

SARS-COV-2 FLUA/FLUB/RSV R-GENE®

Detect & differentiate SARS-CoV-2, Influenza A, Influenza B and RSV in 1 PCR test.

Learn More

VIDAS® KUBE™

VIDAS® KUBE™ is designed to preserve everything labs appreciate about the VIDAS® Solution combined with advanced technology. VIDAS® KUBE™ is a truly flexible, cost-effective automated immunoassay solution providing fast results in complete confidence.

Learn More

VIDAS® 3

With its advanced immunoassay technology and optimized testing protocols, the fully automated VIDAS® 3 benchtop immunoanalyzer empowers your lab with confidence, offering the precise results you need, when you need them. 

Learn More
COVID

COVID-19 / SARS-CoV-2

Because every COVID-19 patient comes with a unique profile and experiences the disease differently, patient management means asking the right questions, finding the right answers and providing appropriate care the entire length of the patient pathway.

Learn More
COVID

BIOFIRE® Respiratory 2.1 and 2.1plus Panels

The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.

Learn More